|
WO2018188761A1
|
|
Method of reducing population size of tregs and/or mdscs
|
|
GB201617339D0
|
|
Therapeutic compounds
|
|
GB201601868D0
|
|
Methods
|
|
WO2016091490A1
|
|
Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics
|
|
JP2016145183A
|
|
Combined chemotherapy
|
|
JP2016128399A
|
|
Immune checkpoint inhibitor combinations
|
|
GB201506128D0
|
|
Chemotherapeutic combinations
|
|
GB201506127D0
|
|
Immune checkpoint inhibitor combinations
|
|
GB201401886D0
|
|
Neurodegenerative therapies
|
|
GB201310464D0
|
|
Compounds
|
|
GB201310460D0
|
|
Compounds
|
|
GB201015537D0
|
|
Compounds
|
|
GB0919194D0
|
|
Compounds
|
|
GB0821616D0
|
|
Compounds
|
|
GB0818074D0
|
|
Treatment of biofilms
|
|
GB0818072D0
|
|
Compounds
|
|
GB0724951D0
|
|
Compounds
|
|
GB0724953D0
|
|
Methods of peptide modification
|
|
GB0605685D0
|
|
Inhibition of tumour growth
|
|
WO2004094462A2
|
|
Methods of peptide preparation
|
